March 27, 2019 7:34pm

… With most of the “sector’s participants” escaping through the sector’s barn door which was left open as the sentiment keypad was turned off

Pre-open indications: 4 Hits and 2 MISS

 

Duty, honor and shareholders should be a mantra – it’s mine!

My “quantamental” blend of styles; must become the “tool” for investors and traders to portfolio enrichment.

 

Markets and indexes:

  • The Dow closed down -32.14 points or -0.13% to 25,625.59
  • The S&P closed down -13.09 points or -0.46% to 2,805.37
  • The NASDAQ was down -48.15 points or -0.63% to 7,643.38

 

Henry’omics:

As I stated this a.m., “I am still concerned, my thought or bad dreams of lingering uncertainties – the unknowns as news is strikingly absent. Which relates back to my thoughts of confidence in share pricing upswings?”

Sector equities fell on Wednesday after a closely watch interest rate fell to its lowest level in more than a year as worries over a possible economic slowdown lingered.

 

Biotech, cell and gene therapy companies were some of the worst-performers as:  BLUE (-$5.26), SAGE (-$4.89), IONS (-$3.15), RGNX (-$2.27) and GBT (-$1.97) ...

  • Tuesday’s downside: QURE (-$2.07), RENE.L (-$2.00), BLFS (-$0.87), RGNX (-$0.39) and VCEL (-$0.35);
  • After Monday’s: RENE.L (-$2.00), QURE (-$1.4), CRSP (-$1.40), BLFS (-$0.75) and BOLD (-$0.68)

Sector equities posting gains were: RENE.L (+$3.50), FIXX (+$0.19), CLBS (+$0.07), BCLI (+$0.07) and PSTI (+$0.017) ...

  • Tuesday’s: BLUE (+$6.59), SAGE (+$4.01), ALNY (+$2.97), RARE (+$2.74) and GBT (+$1.55);
  • After Monday’s: SAGE (+$2.12), GBT (+$1.38), VYGR (+$1.17), RARE (+$1.08) and AXGN (+$1.01)

 

Pre-open post, “the sector verves in the on-going battle of relevance i.e. share value; yet there are many sector “participants” that are just accomplices in crimes against shareholders; check the appreciation “ladder” of share pricing and match it against the net compensation paid to managements in regard to their execution, just one method.” Duty, honor and shareholders should be a mantra – it’s mine!

 

The advance/decline line scenario of 45 covered companies:  

  • The open was negative with the A/DL to 5/38, 1 flat and 1 acquired (AST);
  • The mid-day was negative with an A/DL of 4/39 and 1 flat and 1 acquired;
  • The close was negative with an A/DL of 8/35 and 1 flat and 1 acquired;

 

Pre-open indications:  4 HIT and 2 MISS

  • BioLife Solutions (BLFS) closed down -$0.44 – miss;
  • bluebird bio (BLUE) closed down -$5.26 – hit;
  • uniQure NV (QURE) closed down again -$1.35 – miss;
  • CRISPER Therapeutics (CRSP) closed down -$0.62 – hit;
  • Editas Medicine (EDIT) closed up +$0.24 – hit;
  • Intellia Therapeutics (NTLA) closed down -$0.51 – hit;

 

Tonight’s percentage (%) indicators: 

  • Range of the 8 upside was +0.09% (HSGX) to +4.90% (RENE.L) while the 35 downside ranged from -0.16% (OSIR) to -6.76% (VSTM).

Volume stat: 

  • 0 out of the 8 upside had higher (than the 3 month average) volume
  • 6 out of the 35 downside experienced greater volume (than the 3 month average)

1 flat – BSTG with 1 acquired: 1 (AST)

 

The iShares NASDAQ Biotechnology (IBB) indicator:

  • Wednesday was down -1.39%;
  • Tuesday was up +1.86%;
  • Monday was up +0.14%;
  • Friday was down -3.39%;
  • Thursday was down -1.07%;
  • Last Wednesday was down -0.59%;

 

March sessions:

Wednesday closed NEGATIVE with 35 decliners, 8 advancers, 1 flat and 1 acquired;

Tuesday closed POSITIVE with 17 decliners, 26 advancers, 2 flats and 1 acquired;

Monday closed POSITIVE with 21 decliners, 23 advancers, 0 flats and 1 acquired;

Friday closed NEGATIVE with 40 decliners, 2 advancers, 2 flats and 1 acquired;

Thursday closed POSITIVE with 12 decliners, 31 advancers, 1 flat and 1 acquired;

Wednesday closed NEGATIVE with 25 decliners, 18 advancers, 1 flat and 1 acquired;

Tuesday closed NEGATIVE with 22 decliners, 19 advancers, 3 flats and 1 acquired;

Monday (3/18) closed POSITIVE with 17 decliners, 27 advancers and 1 acquired;

Friday closed POSITIVE with 12 decliners, 32 advancers and 1 flat;

Thursday closed NEGATIVE with 30 decliners, 13 advancers and 2 flats;

Wednesday closed POSITIVE with 12 decliners, 30 advancers and 3 flats;

Tuesday closed POSITIVE with 13 decliners, 30 advancers and 2 flats;

Monday (3/11) closed POSITIVE with 7 decliners, 37 advancers and 1 flat;

Friday closed POSITIVE with 20 decliners, 22 advancers and 3 flats;

Thursday closed POSITIVE with 14 decliners, 29 advancers and 2 flats;

Wednesday closed NEGATIVE with 39 decliners, 5 advancers and 1 flat;

Tuesday (3/4) closed POSITIVE with 17 decliners, 23 advancers and 5 flats;

Monday (3/1) closed NEGATIVE with 24 decliners, 18 advancers and 3 flats;

Friday (3/1) closed POSITIVE with 11 decliners, 32 advancers and 2 flats;

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.